Noul's miLab registered FDA's Class I

Quick Summary:

South Korea's Noul Co., an in-vitro diagnostics maker and artificial intelligence (AI)-based blood and cancer diagnostic platforms company, said on Thursday it received the registration of four medical devices as Class I products with the US Food and Drug Administration (FDA).

The registered products include Noul’s "miLab Platform," an automated device equipped with solid staining and imaging technologies, two diagnostic cartridges for malaria and blood analysis, and a fixation solution (SafeFix).

The US in-vitro diagnostic market is expected to grow at an annual rate of 7.7%, from $33.9 billion in 2023 to $56.9 billion by 2030.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: Economy

Markets: South Korea

Topics: Blood Products Step Intelligence Registration Solution Company Diagnostic Noul Korea In-vitro

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-11-28 @ 17:24:14 (3 hours ago)

News Timezone: GMT +8:00

News Source URL: kedglobal.com

Language: English

Article Length: 136 words

Reading Time: 1 minutes read

Sentences: 10 lines

Sentence Length: 14 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Korea Economic Daily

News ID: 23915650

View Article Analysis

About Korea Economic Daily

Main Topics: Economy

Official Website: kedglobal.com

Update Frequency: 10 posts per day

Year Established: 1964

Headquarters: South Korea

News Last Updated: ago

Coverage Areas: South Korea

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #91

Publisher Details

Frequently Asked Questions